Sarcopenia in patients with non‐alcoholic fatty liver disease: is it a clinically significant entity?
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Summary: Sarcopenia, described as the loss of muscle mass and/or strength, is gaining importance as it can be increasingly related to many chronic diseases. It is also associated with chronic liver disease, and recently it has been more frequently linked to non‐alcoholic fatty liver disease (NAFLD) in particular. Both sarcopenia and NAFLD are subject to complex and intermingled pathophysiological processes, of which some are in common. Furthermore, it is presently unclear if sarcopenia directly contributes to NAFLD or vice versa. The mechanisms that are involved may include obesity, insulin resistance, vitamin D deficiency, aging, physical inactivity and certain cytokines. Current clinical evidence is subject to an important heterogeneity in methods and definitions, with additionally also a relative overrepresentation of evidence in Asian ethnicities. Nonetheless, all studies so far point towards the same association between sarcopenia and NAFLD, including an association with NAFLD‐severity and NAFLD‐related fibrosis. Since the field is in its infancy, clear definitions and further research are needed to aid to improve understanding of the association between NAFLD and sarcopenia. This can eventually lead to additional potential therapeutic interventions. This review attempts to give an overview of the current published literature that links sarcopenia to NAFLD, followed by a discussion of the presumably involved pathophysiological factors, and ends by discussing current unmet needs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Mechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814 · cited 3×
“The prevalence of obesity is rising worldwide and with the increasing prevalence amongst young adults and children, estimated at 28% and 47%, respectively, obesity will be one of the future major health problems (7,8).”
BackgroundEkstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287 · cited 2×
“Cardiovascular disease (CVD) is the main cause of death in patients with NAFLD (14,29,30).”
BackgroundAge-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases
Kalyani, R. R., Corriere, M., & Ferrucci, L. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70034-8 · Cited by 1,102
Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives
Rolland, Y., Czerwinski, S., van Kan, G. A., Morley, J. E., Cesari, M., Onder, G., Woo, J., Baumgartner, R., Pillard, F., Boirie, Y., et al. (2008) · The Journal of nutrition, health and aging · doi:10.1007/bf02982704 · Cited by 1,071
Insulin resistance: a metabolic pathway to chronic liver disease
Bugianesi, E., McCullough, A. J., & Marchesini, G. (2005) · Hepatology · doi:10.1002/hep.20920 · Cited by 900
Kalinkovich, A., & Livshits, G. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.09.008 · Cited by 882 · cited 2×
“As a result, adipose tissue and skeletal muscle inflammation continues to be maintained and synergistically leads to an additional deterioration of muscle mass (35).”
BackgroundIntermuscular fat: a review of the consequences and causes
Addison, O., Marcus, R. L., LaStayo, P. C., & Ryan, A. S. (2014) · International Journal of Endocrinology · doi:10.1155/2014/309570 · Cited by 656 · cited 2×
“During aging, lipids may accumulate in the muscle (41).”
BackgroundHepatokines: Linking nonalcoholic fatty liver disease and insulin resistance
Meex, R. C. R., & Watt, M. J. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.56 · Cited by 631 · cited 1×
“Although no direct link has been proven so far, hepatokines affect insulin signalling in muscles (45) and could therefore affect muscle mass and/or quality.”
BackgroundSrikanthan, P., Hevener, A. L., & Karlamangla, A. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010805 · Cited by 600
Cited by
Nachit, M., Kwanten, W. J., Thissen, J.-P., Op De Beeck, B., Van Gaal, L., Vonghia, L., Verrijken, A., Driessen, A., Horsmans, Y., Francque, S., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.037 · Cited by 114
Self-citationLinge, J., Ekstedt, M., & Dahlqvist Leinhard, O. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2020.100197 · Cited by 98
“Several studies have, conversely, reported a positive association between NAFLD and current sarcopenia definitions.(8) However, the conclusion of whether there is an association or not seems to greatly depend on different ways of defining sarcopenia and normalising muscle quantity for body size.”
ResultVolpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Triggiani, D., Donghia, R., Crudele, L., Rinaldi, R., Sabbà, C., et al. (2022) · Nutrients · doi:10.3390/nu14214673 · Cited by 84
Nachit, M., De Rudder, M., Thissen, J., Schakman, O., Bouzin, C., Horsmans, Y., Vande Velde, G., & Leclercq, I. A. (2021) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12646 · Cited by 82
Kim, B.-J., Ahn, S. H., Lee, S. H., Hong, S., Hamrick, M. W., Isales, C. M., & Koh, J.-M. (2019) · Aging · doi:10.18632/aging.102068 · Cited by 42
“Insulin resistance and chronic inflammation have been the most frequently proposed mechanisms, and both are hypothetically plausible [28, 30].”
Background
Metadata
- Authors
- De Fré, C. H., De Fré, M. A., Kwanten, W. J., Op de Beeck, B. J., Van Gaal, L. F., & Francque, S. M.
- Venue
- Obesity Reviews
- Publisher
- Wiley
- Published
- 2018-11-25
- Volume
- 20
- Issue
- 2
- Pages
- 353-363
- ISSN
- 1467-7881 (ISSN-L)
- 1467-789X
- OpenAlex
- W2902727166
- Cited by
- 53
- References
- 28
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sarcopenia in patients with non‐alcoholic fatty liver disease: is it a clinically significant entity? https://app.cochat.ai/papers/10.1111/obr.12776
- The paper
- De Fré, C. H., De Fré, M. A., Kwanten, W. J., Op de Beeck, B. J., Van Gaal, L. F., & Francque, S. M. (2019). Sarcopenia in patients with non‐alcoholic fatty liver disease: is it a clinically significant entity? Obesity Reviews. https://doi.org/10.1111/obr.12776
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.